Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Operating Margin (2018 - 2026)

Sunshine Biopharma filings provide 9 years of Operating Margin readings, the most recent being 20.87% for Q4 2025.

  • On a quarterly basis, Operating Margin rose 37.0% to 20.87% in Q4 2025 year-over-year; TTM through Dec 2025 was 17.15%, a 63.0% decrease, with the full-year FY2025 number at 17.15%, down 49.0% from a year prior.
  • Operating Margin hit 20.87% in Q4 2025 for Sunshine Biopharma, down from 11.54% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 11.54% in Q3 2025 to a low of 3184.5% in Q1 2021.
  • Median Operating Margin over the past 5 years was 21.54% (2025), compared with a mean of 439.95%.
  • Biggest five-year swings in Operating Margin: tumbled -284493bps in 2021 and later soared 218701bps in 2022.
  • Sunshine Biopharma's Operating Margin stood at 328.52% in 2021, then tumbled by -81bps to 593.01% in 2022, then soared by 97bps to 15.46% in 2023, then crashed by -37bps to 21.24% in 2024, then rose by 2bps to 20.87% in 2025.
  • The last three reported values for Operating Margin were 20.87% (Q4 2025), 11.54% (Q3 2025), and 21.83% (Q2 2025) per Business Quant data.